Middle East and Africa Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious

Middle East and Africa Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)

The Middle East & Africa monoclonal antibodies market is expected to reach US$ 5,741.1 million by 2028 from US$ 3,198.9 million in 2021. The market is estimated to grow at a CAGR of 8.7% from 2021-2028.

The high focus of pharmaceutical giants on developing novel monoclonal antibodies resulted in significant research collaborations that can pave the way to key market share in the coming years. New manufacturers seek strategic collaborations to increase uptake of such novel techniques, as they intend to enter a highly competitive market to sustain their position. For records, in October 2017, Incyte and Macro Genics, Inc. announced a partnership and license agreement for MGA012, an investigational monoclonal antibody of Macro Genics, Inc. Such factors are projected to support the Middle East & Africa market growth in the coming years. Furthermore, strategic research collaborations also play a vital role in detecting pharmacological actions of m ABs soon after the diagnosis.

The demand for monoclonal antibody-based products in Saudi Arabia have a high success rate in clinical development and is reported that the probability of FDA approvals for m ABs in Phase 1 of development in ~14.1% that is almost twice the approval rate of small molecule drugs (~7.6%). On the other hand, the IAVI report states that with the onset of pandemic worldwide many biopharmaceutical companies sell m ABs based products at affordable prices. For example, in South Africa, Roche sells its breast cancer m AB trastuzumab as both Herceptin the original brand as a second brand called Hercelon. Apart from that, as availability of these m ABs is limited, various pharmaceutical companies are conducting clinical trials in middle-income counties. For example, Merck is conducting clinical trials in several middle-income countries such as South Africa, Colombia, and Malaysia. Such aforementioned factors have positive influence in the regional market thereby witnessing high adoption of monoclonal antibody in Middle East and Africa region amid COVID-19 pandemic.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The Middle East & Africa monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.

Middle East & Africa Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Monoclonal Antibodies Market Segmentation

By Source

Human Humanized Chimeric Murine By Production Method

In-Vitro In-Vivo By Indication

Cancer Autoimmune Diseases Infectious Diseases Inflammatory Diseases Microbial Diseases Others By Application

Therapeutic Applications Diagnostic Applications Research Applications By End-User

Hospitals Research Institutes Others By Country

Middle East & Africa UAE Saudi Arabia South Africa Rest of Middle East & Africa Companies Mentioned

Novartis AG Pfizer Inc. Glaxo Smith Kline plc. Amgen Inc DAIICHI SANKYO COMPANY, LIMITED F. Hoffmann-La Roche Ltd. Astra Zeneca Bayer AG Bristol-Myers Squibb Company

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa monoclonal antibodies market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa monoclonal antibodies market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.